Phase 1Completed
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
A Single-center, Open-label Positron Emission Tomography Study to Evaluate the Time-course of Displacement of [11C]UCB-J by Brivaracetam and Levetiracetam in Healthy Volunteers
- Sponsor
- UCB Pharma (Industry)
- Enrolment
- 13 enrolled
- Conditions
- Healthy Volunteers
- Interventions
- [11C]UCB-J; Brivaracetam; Levetiracetam; Brivaracetam
- Ages
- adults
- Registry
- NCT02602860
Full record on ClinicalTrials.gov
From the registry
This study will estimate how fast two antiepileptic drugs (Levetiracetam and Brivaracetam) enter the human brain. Brain imaging will be used to measure how quickly the radioactive probe \[11C\]UCB-J exits the brain when Levetiracetam or Brivaracetam are given. This will be used to estimate how fast the antiepileptic drugs enter the brain.
Primary outcomes
- Level of synaptic vesicle glycoprotein 2A (SV2A) receptor occupancy during the displacement scans
- Equilibrium tissue to plasma activity ratio (VT) of [11C]UCB-J
- Tracer displacement halftimes
- Tracer-exit corrected halftimes of Brivaracetam or Levetiracetam entry
History
Last registry update
Primary completion
Started
Registered